What's Happening?
UCSF Benioff Children's Hospitals are actively working to expand treatment options for pediatric sarcoma and osteosarcoma, conditions for which outcomes have remained largely unchanged for decades. Researchers, including pediatric hematologist-oncologist
Amanda Marinoff, MD, are moving away from a 'one-size-fits-all' approach towards precision medicine. This involves tailoring therapy based on a patient's risk and tumor biology. A key component of this strategy is leveraging the UCSF500 DNA and RNA sequencing platform, which is already integrated into clinical care at UCSF. This platform allows physicians to define molecular features that guide diagnoses, prognoses, and treatment decisions. Additionally, UCSF is participating in the CaIRS (Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas) phase 1 trial, exploring a new drug combination for these cancers, and is part of a $15 million multi-institutional grant from Break Through Cancer focused on osteosarcoma.
Why It's Important?
The efforts at UCSF are critical because pediatric sarcoma and osteosarcoma have seen little improvement in treatment outcomes for over 40 years, with many children and adolescents facing poor prognoses. By adopting a precision medicine approach, UCSF aims to identify high-risk patients who require intensified or alternative therapies, while also de-intensifying treatment for those likely to respond well to standard care, thereby sparing them unnecessary toxicity. The integration of DNA and RNA sequencing into routine clinical workflows provides a significant advantage, allowing for more accurate molecular profiling of tumors. This personalized strategy has the potential to revolutionize treatment for these aggressive cancers, offering hope for improved survival rates and quality of life for young patients. The collaborative nature of these initiatives, including multi-institutional grants, accelerates the pace of discovery and translation into clinical trials.
What's Next?
UCSF's immediate next steps include continuing the CaIRS phase 1 trial to evaluate the safety and appropriate dosing of the cabozantinib and ifosfamide combination, while also looking for early signals of activity. The team is also focused on developing risk-adapted therapies, which will involve using molecular features to predict patient responses and implement novel therapeutic strategies earlier in the treatment process. The multi-institutional grant from Break Through Cancer will facilitate data and resource sharing among experts, with the goal of uncovering new therapies and biological understandings of osteosarcoma, which will then be translated into new clinical trials. Researchers anticipate that these collaborative projects will generate important insights that will lead to the establishment of new treatments for osteosarcoma in the coming years.
Beyond the Headlines
The shift towards precision medicine in pediatric oncology at UCSF signifies a broader paradigm change in cancer treatment, emphasizing individualized care over standardized protocols. This approach not only addresses the biological complexity of cancer but also highlights the ethical considerations of minimizing harm and maximizing benefit for vulnerable patient populations like children. The integration of advanced genomic sequencing into routine clinical care sets a precedent for how medical institutions can leverage technology to improve patient outcomes. Furthermore, the 'radical collaboration' fostered by initiatives like the Break Through Cancer grant underscores the growing recognition that complex medical challenges require interdisciplinary and multi-institutional efforts, pushing the boundaries of traditional research models and accelerating the translation of scientific discoveries into tangible patient benefits.
